Pharmacological treatment of dementia: a scoping review of systematic reviews

Esther M M van de Glind; Wynanda A van Enst; Barbara C van Munster; Marcel G M Olde Rikkert; Philip Scheltens; Rob J P M Scholten; Lotty Hooft

doi:10.1159/000353892

Pharmacological treatment of dementia: a scoping review of systematic reviews

Esther M M van de Glind
, Wynanda A van Enst
, Barbara C van Munster
, Marcel G M Olde Rikkert
, Philip Scheltens
, Rob J P M Scholten
, Lotty Hooft

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Until now, multiple reviews on the pharmacological treatment of dementia have been published.

METHODS: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia.

CONCLUSIONS: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade.

Original language	English
Pages (from-to)	211-28
Number of pages	18
Journal	Dementia and Geriatric Cognitive Disorders
Volume	36
Issue number	3-4
DOIs	https://doi.org/10.1159/000353892
Publication status	Published - 2013

Keywords

Aged
Aged, 80 and over
Behavior
Cholinesterase Inhibitors
Cognition Disorders
Data Interpretation, Statistical
Dementia
Dementia, Vascular
Disease Progression
Dopamine Agents
Early Medical Intervention
Humans
Memantine
Nootropic Agents
Parkinson Disease
Publication Bias

Access to Document

10.1159/000353892

Cite this

@article{a83cce7ca430430c99a01ec9547bdbc4,

title = "Pharmacological treatment of dementia: a scoping review of systematic reviews",

abstract = "BACKGROUND: Until now, multiple reviews on the pharmacological treatment of dementia have been published.METHODS: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia.CONCLUSIONS: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade.",

keywords = "Aged, Aged, 80 and over, Behavior, Cholinesterase Inhibitors, Cognition Disorders, Data Interpretation, Statistical, Dementia, Dementia, Vascular, Disease Progression, Dopamine Agents, Early Medical Intervention, Humans, Memantine, Nootropic Agents, Parkinson Disease, Publication Bias",

author = "\{van de Glind\}, \{Esther M M\} and \{van Enst\}, \{Wynanda A\} and \{van Munster\}, \{Barbara C\} and \{Olde Rikkert\}, \{Marcel G M\} and Philip Scheltens and Scholten, \{Rob J P M\} and Lotty Hooft",

note = "{\textcopyright} 2013 S. Karger AG, Basel.",

year = "2013",

doi = "10.1159/000353892",

language = "English",

volume = "36",

pages = "211--28",

journal = "Dementia and Geriatric Cognitive Disorders",

issn = "1420-8008",

publisher = "S. Karger AG",

number = "3-4",

}

TY - JOUR

T1 - Pharmacological treatment of dementia

T2 - a scoping review of systematic reviews

AU - van de Glind, Esther M M

AU - van Enst, Wynanda A

AU - van Munster, Barbara C

AU - Olde Rikkert, Marcel G M

AU - Scheltens, Philip

AU - Scholten, Rob J P M

AU - Hooft, Lotty

PY - 2013

Y1 - 2013

N2 - BACKGROUND: Until now, multiple reviews on the pharmacological treatment of dementia have been published.METHODS: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia.CONCLUSIONS: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade.

AB - BACKGROUND: Until now, multiple reviews on the pharmacological treatment of dementia have been published.METHODS: We performed a scoping review to summarize research findings and to identify gaps in the existing literature. We searched the literature and assessed the risk of bias of the included reviews. A team of clinical experts assessed the fields in which more research is necessary. Fifty-five reviews with a low risk of bias were included, most of them concerning the treatment of cognitive decline (n = 16) and behavioral symptoms (n = 10) in Alzheimer's disease (AD). For cognitive impairment, cholinesterase inhibitors (n = 13) and memantine (n = 7) were described most frequently. Little information was found about the treatment of depression in dementia.CONCLUSIONS: For many current treatments, there is sufficient evidence. New research should focus on the symptomatic treatment of the earliest and most salient complaints in AD as well as on disease-modifying interventions acting at the level of the amyloid cascade.

KW - Aged

KW - Aged, 80 and over

KW - Behavior

KW - Cholinesterase Inhibitors

KW - Cognition Disorders

KW - Data Interpretation, Statistical

KW - Dementia

KW - Dementia, Vascular

KW - Disease Progression

KW - Dopamine Agents

KW - Early Medical Intervention

KW - Humans

KW - Memantine

KW - Nootropic Agents

KW - Parkinson Disease

KW - Publication Bias

U2 - 10.1159/000353892

DO - 10.1159/000353892

M3 - Article

C2 - 23941762

SN - 1420-8008

VL - 36

SP - 211

EP - 228

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

IS - 3-4

ER -

Pharmacological treatment of dementia: a scoping review of systematic reviews

Abstract

Keywords

Access to Document

Fingerprint

Cite this